Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes

Migraine is prevalent during pregnancy. Antimigraine medications such as dihydroergotamine (DHE) and triptans have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains. We compared the risk of prematurity, low birth weight (LBW), major congenital malfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Bérard, Anick, Strom, Shannon, Zhao, Jin-Ping, Kori, Shashi, Albrecht, Detlef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481540/
https://www.ncbi.nlm.nih.gov/pubmed/34588467
http://dx.doi.org/10.1038/s41598-021-97092-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481540/
https://www.ncbi.nlm.nih.gov/pubmed/34588467
http://dx.doi.org/10.1038/s41598-021-97092-y

Ejemplares similares